Genzyme/Isis Gear Up For Long-awaited Kynamro Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme said it is ready to deliver product, but complying with the REMS that helped pave the way for approval is a time-limiting factor for launching the familial hypercholesterolemia drug. Drug will be priced at $176,000 per year, significantly lower than Aegerion’s competing Juxtapid.